Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 20Lymphoma, T-Cell, Cutaneous 19Lymphoma, T-Cell 17Lymphoma 16Lymphoma, Large B-Cell, Diffuse 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large-Cell, Anaplastic 8Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Lung Neoplasms 3Hematologic Neoplasms 3

Interventions

Cyclophosphamide 63fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 34Vincristine 30Methotrexate 30Etoposide 29Cytarabine 28Dexamethasone 27Whole-Body Irradiation 25Doxorubicin 25Mycophenolic Acid 23Prednisone 22Tacrolimus 21Filgrastim 21Busulfan 19Antilymphocyte Serum 18venetoclax 17nelarabine 17Cyclosporine 17Calcium Dobesilate 17merphos 15Rituximab 14Radiotherapy 14Methylprednisolone 13Bortezomib 13pegaspargase 12dexamethasone acetate 11dexamethasone 21-phosphate 11Melphalan 11prednylidene 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × romidepsin × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡